Access and Support

AMVUTTRA® is accessible and affordable for most patients, regardless of insurance type

AMVUTTRA® is accessible and affordable for most patients, regardless of insurance type

  • 99% of patients have confirmed AMVUTTRA coverage1
  • AMVUTTRA access through Medicare Fee-for-Service (FFS) Part B does not require a prior authorization (PA). For Medicare Advantage or commercially insured patients, PAs are standard for specialty medications
  • Most patients live within 10 miles of a treatment center1
Pay $0 out of pocket icon

Patient Support Through Alnylam Assist®

Alnylam Assist® helps with starting treatment and offers product support services patients can count on, including:

  • Benefits verification, treatment site identification, Prior Authorization education, and information about coding and reimbursement
  • Financial assistance options for eligible patients,* including copay support, coverage delay assistance, and patient assistance programs
  • Support to help patients stay on track with treatment and educational resources throughout their journey

*Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

Alnylam Assist logo

Alnylam Assist®

8am-6pm, Monday-Friday
Phone: 1-833-256-2748
Fax: 1-833-256-2747
Learn more: AlnylamAssist.com

Alnylam Assist® Brochure

Learn more about patient support available through Alnylam Assist®

Download brochure

How to Get Started With AMVUTTRA

Your patients may receive AMVUTTRA through health systems, specialty infusion providers, in the clinic, or in the home†

Electric start form icon

Electronic Start Form

Complete and submit the Electronic Start Form online with your patient

Electronic Start Form

Downloadable start form icon

Downloadable Start Form‡

Print, complete with your patient, and fax the Start Form to 1-833-256-2747

Download Start Form

Resources icon

Resources

To access helpful resources or to submit a Start Form, visit Alnylam Assist®

To learn more, contact your local Alnylam representative

†If covered by the patient's insurance.

‡If you are not able to obtain your patient's signature, an Alnylam Case Manager can follow up with them to obtain their consent.

UP NEXT: Resources Up Next icon

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
  • polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information .

Reference

  1. Data on file. Alnylam Pharmaceuticals, Inc.